{"id":483544,"date":"2021-04-28T16:04:49","date_gmt":"2021-04-28T20:04:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/"},"modified":"2021-04-28T16:04:49","modified_gmt":"2021-04-28T20:04:49","slug":"adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/","title":{"rendered":"Adverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema"},"content":{"rendered":"
\n

REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg\/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.<\/p>\n

In the interests of patient safety, Adverum has decided to immediately unmask the INFINITY Phase 2 study to better understand this event and to help identify and manage any similar potential risk to other patients in this study, which completed patient dosing in December 2020. Additionally, the company is conducting a thorough review of data from the ADVM-022 program and plans to report its findings as the analysis progresses.<\/p>\n

\u201cThe safety of every patient who is participating in our clinical studies with our gene therapy is the utmost priority for us at Adverum,\u201d said Laurent Fischer, M.D., chief executive officer of Adverum. \u201cWe are fully committed to thoroughly assessing this case and ongoing monitoring of this patient and all patients treated with ADVM-022 with our investigators, data monitoring committee (DMC), scientific advisory board, and healthcare authorities.\u201d<\/p>\n

The INFINITY study is evaluating two doses of a single intravitreal (IVT) injection of ADVM-022 gene therapy, either a high dose 6 x 10^11 vg\/eye or low dose 2 x 10^11 vg\/eye. As of December 2020, the INFINITY study was fully enrolled, and all patients completed dosing of the single IVT injection of ADVM-022. All patients continue to be evaluated regularly during the monitoring phase of this study. Adverum is working closely with the DMC and the study sites to proactively develop additional recommendations for patient monitoring and management. All clinical trial sites, as well as the U.S. Food and Drug Administration (FDA), have been advised of this case.<\/p>\n

\n About the INFINITY Phase 2 Trial of ADVM-022 in DR\/DME<\/strong>
\n
INFINITY is a Phase 2, multi-center, randomized, double-masked, active comparator-controlled trial designed to assess a single intravitreal (IVT) injection of ADVM-022 in patients with diabetic macular edema (DME), the most common cause of vision loss in patients with diabetic retinopathy (DR).<\/p>\n

The INFINITY trial enrolled 36 patients and is designed to demonstrate superior control of disease activity following a single IVT injection of ADVM-022 compared to a single aflibercept injection, as measured by time to worsening of DME disease activity. Participants in this double-masked trial were randomized to one of three arms for their study eye treatment: Arm 1 received high dose (6 x 10^11 vg\/eye) of ADVM-022, Arm 2 received low dose (2 x 10^11 vg\/eye) of ADVM-022, and Arm 3 received aflibercept at a dose of 2 mg. Additional objectives include assessments of treatment burden, visual acuity, retinal anatomy, and safety outcomes. For additional information about the INFINITY trial, please visit www.clinicaltrials.gov<\/a> using Identifier NCT#04418427 or\u00a0www.INFINITYclinicaltrial.com<\/a>.<\/p>\n

\n About Adverum Biotechnologies<\/strong>
\n
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com<\/a>.<\/p>\n

\n Forward-Looking Statements <\/strong>
\n
Statements contained in this press release regarding the events or results that may occur in the future are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include risks described in Adverum\u2019s Quarterly Report on Form 10-K for the year ended December 31, 2020 and any subsequent filings with the SEC under the heading \u201cRisk Factors.\u201d All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n


\n
\n \n <\/div>\n

\n
Investor Relations Contacts\r\nMyesha Lacy\r\nAdverum Biotechnologies, Inc.\r\nT: 650-649-1257 \r\nE: mlacy@adverum.com\r\n\r\nAmy Figueroa\r\nAdverum Biotechnologies, Inc.\r\nT: 650-823-2704\r\nE: afigueroa@adverum.com\r\n\r\nMedia Contact \r\nAndrea Cohen \r\nSam Brown Inc. \r\nT: 917-209-7163 \r\nE: andreacohen@sambrown.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg\/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye. In the interests of patient safety, Adverum has decided to immediately unmask the INFINITY Phase 2 study to better understand this event and to help identify and manage any similar potential risk to other … <\/p>\n
Continue reading “Adverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-483544","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAdverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg\/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye. In the interests of patient safety, Adverum has decided to immediately unmask the INFINITY Phase 2 study to better understand this event and to help identify and manage any similar potential risk to other … Continue reading "Adverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-28T20:04:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTgzMSM0MTQ0OTgzIzIwMDYyMTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema\",\"datePublished\":\"2021-04-28T20:04:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\\\/\"},\"wordCount\":694,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTgzMSM0MTQ0OTgzIzIwMDYyMTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\\\/\",\"name\":\"Adverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTgzMSM0MTQ0OTgzIzIwMDYyMTI=\",\"datePublished\":\"2021-04-28T20:04:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTgzMSM0MTQ0OTgzIzIwMDYyMTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTgzMSM0MTQ0OTgzIzIwMDYyMTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/","og_locale":"en_US","og_type":"article","og_title":"Adverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema - Market Newsdesk","og_description":"REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg\/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye. In the interests of patient safety, Adverum has decided to immediately unmask the INFINITY Phase 2 study to better understand this event and to help identify and manage any similar potential risk to other … Continue reading \"Adverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-28T20:04:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTgzMSM0MTQ0OTgzIzIwMDYyMTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema","datePublished":"2021-04-28T20:04:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/"},"wordCount":694,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTgzMSM0MTQ0OTgzIzIwMDYyMTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/","name":"Adverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTgzMSM0MTQ0OTgzIzIwMDYyMTI=","datePublished":"2021-04-28T20:04:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTgzMSM0MTQ0OTgzIzIwMDYyMTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTgzMSM0MTQ0OTgzIzIwMDYyMTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adverum\u00a0Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/483544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=483544"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/483544\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=483544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=483544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=483544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}